News
Enhertu scores ‘impressive’ new data in HER2 breast cancer
AstraZeneca and Daiichi Sankyo have reported updated results from a phase II trial of Enhertu, which continued to demonstrate ‘impressive’ efficacy in patients with HER2-positive metastatic breast cancer.